It has been shown that dry coating cohesive active pharmaceutical ingredients (APIs) with nano-silica can improve packing and flow of their blends, facilitating high speed direct compression tableting. This paper examines the broader scope and generality of previous work by examining three fine APIs; micronized Acetaminophen (mAPAP), coarse Acetaminophen (cAPAP) and micronized Ibuprofen (mIBU), and considers dry coating with both hydrophobic or hydrophilic nano-silica to examine the effect not only on packing density and flow of their blends, but also dissolution and tensile strength of their tablets. The impact of the excipient size on blend and tablet properties are also investigated, indicating blend flow is most improved when matching API particle size with excipient particle size. In all cases where the API is dry coated, the blend packing and flow improve, so as to suggest such high drug loaded blends could enable direct compression. Using dry coated API along with finer excipients in blends lead to improved hardness of the corresponding tablets. Interestingly, dissolution profiles show dry coated API tablets generally have faster dissolution rates, regardless of silica hydrophilicity, suggesting API powder deagglomeration via nano-silica coating plays a crucial role. The most significant conclusion is that, although there are differences in properties of blends that depend on the API, hydrophobic or hydrophilic nanosilica coating, as well as large or fine excipients, in all cases, dry coating of APIs significantly improves the possibility of using the specific blend at high drug loading in direct compression tableting.
Introduction
The simplest way to produce tablets from pharmaceutical blends is via direct compression, in which a blend is filled into a die and compressive forces are applied to produce a tablet. Additionally, direct compression tableting holds numerous advantages over similar competing pharmaceutical tablet production processes such as wet granulation or roller compaction; the most important being that direct compression involves fewer unit operations (Garg et al., 2015; Jivraj et al., 2000) . Another crucial advantage of direct compression tableting is the ability to use heat and moisture sensitive APIs in processing (Jivraj et al., 2000) , as it opens up the possibility of using this processing technique for a wider range of drug products. Furthermore, research has demonstrated that tablets made via direct compression show faster dissolution rates and require lower compaction forces during processing compared to tablets made from the wet granulation method (Katdare and Bavitz, 1987) . Faster dissolution rates equate to quicker bioavailability (Amidon, 1995; Liversidge and Cundy, 1995) and thus, a quicker therapeutic response in the patient. Lower compaction pressures result in lower energy consumption during the process, which can improve logistics. These reasons make direct compression tableting the process of choice for tablet manufacturing, particularly when high speed direct compression tableting is feasible. This processing option couples the advantages of the improved tablet and process qualities of direct compression with quick, continuous manufacturing.
However, there are challenges to implementing high speed direct compression tableting, some of which depend on the properties of the raw material input. In order to achieve consistent die filling and produce tablets with adequate tensile strength, powders must flow well and have good packing respectively (Jivraj et al., 2000) . Although finer APIs are preferred due to their potentially faster dissolution rates (Adkins and Faulds, 1997; Atkinson et al., 1962; Englund and Johansson, 1981; Hargrove et al., 1989; Jounela et al., 1975; Kraml et al., 1962; Liversidge and Cundy, 1995; Munoz et al., 1994; Vogt et al., 2008) , it is difficult to achieve adequate flow and packing properties due to the fact that micronization often results in higher cohesion in the powder bed (Chen et al., 2008; Yang et al., 2005) . This typically leads formulators to add large particle size excipients (> 100 µm) to improve the flow and packing of the powder blend (Jivraj et al., 2000) . However, blending large excipients with fine APIs may lead to segregation issues (Enstad, 2001; Huang et al., 2017) . In addition, the drug loading of fine APIs is typically restricted to 30% or below (Jivraj et al., 2000) . At higher drug loadings, since there is a larger percentage of API, the powder blend will tend to be more cohesive and not have adequate properties required for direct compression (Han et al., 2013a; Huang et al., 2015b) . Drug products with high drug loading (> 50%) offer many potential advantages such as increased therapeutic response due to higher drug concentration, increased patient compliance due to smaller tablets or lower number of tablets per dose, and lower susceptibility to drug content uniformity issues Johnson, 1972) .
Previous studies have investigated the use of dry coating as a way to reduce interparticle cohesion, and thus improve powder properties such as flow, packing, fluidization and compaction (Capece et al., 2014; Chen et al., 2008; Han et al., 2011 Han et al., , 2013a Huang et al., 2015a Huang et al., ,b, 2017 Jallo et al., 2012; Pfeffer et al., 2001; Qu et al., 2015; Yang et al., 2005; Zhou et al., 2011) . Dry coating involves surface modification of host particles by coating them with nano-sized guests, which are typically finer by orders of magnitude relative to the host particles. This reduces the surface roughness of the host particles to the nano-scale and create physical separation between them, which in turn reduces the interparticle cohesion (Chen et al., 2008; Yang et al., 2005) , resulting in improved powder properties. Previously, dry coating has been specifically implemented on fine APIs to improve flow and packing (Capece et al., 2014 (Capece et al., , 2015 (Capece et al., , 2016 (Capece et al., , 2017 Ghoroi et al., 2013a,b; Han et al., 2011 Han et al., , 2013a Huang et al., 2015a Huang et al., ,b, 2017 Jallo et al., 2012; Mullarney et al., 2011; Zhang and Zhou, 2009; Zhou et al., 2010) . Furthermore, dry coated APIs have been incorporated into high drug loaded blends, which have improved blend and tablet properties compared to high drug loaded blends with uncoated APIs (Han et al., 2013a; Huang et al., 2015b) , allowing them to be considered for high speed direct compression tableting.
In this work, various dry coated APIs are used to produce high drug loaded blends, and their subsequent powder properties are analyzed. Among these APIs are micronized Acetaminophen (mAPAP), coarse Acetaminophen (cAPAP) and micronized Ibuprofen (mIBU). The APIs were dry coated with either hydrophobic (R972P) or hydrophilic (M5P) nano-silica to improve flow and packing properties. The dry coated APIs were used to make pharmaceutical blends with either large or fine particle size excipients. After characterization of the pharmaceutical blends, tablets were produced from the blends, and were characterized for tensile strength and dissolution profiles. Previous studies have demonstrated improved blend and tablet properties in similar high drug loaded blends and tablets (Han et al., 2013a; Huang et al., 2015b) , but only for one API, one excipient size group or one nano-silica. The goal of this work is to identify trends in blend and tablet properties that transcend one specific API, excipient size group or nano-silica, as these trends would have a broader impact on production routes and formulation design in the pharmaceutical industry.
Materials and methods

Materials
Two as received APIs are used in this study: micronized Acetaminophen (mAPAP) was purchased from Mallinckrodt Inc., USA and coarse Acetaminophen (cAPAP) was purchased from Changshu Huagang Pharmaceutical Co., Ltd. China. A third API, Ibuprofen 90, which is a grade of pure Ibuprofen, was purchased from BASF, USA, then milled to finer particle size. Nano-silica was used as the dry coating guest. hydrophobic Aerosil R972P nano-silica and hydrophilic CAB-O-SIL M5P nano-silica were purchased from Evonik, USA and Cabot Corporation, USA respectively. Excipients used for blend formulations include fillers, binders, a disintegrant and a lubricant. Two grades of both Microcrystalline Cellulose and lactose were used in this study: large particle size Avicel PH-102 (Avicel 102, FMC Biopolymer, USA), fine Avicel PH-105 (Avicel 105, FMC Biopolymer, USA), spray dried large particle size lactose Pharmatose DC11 (Pharmatose, DFE Pharma, USA) and fine lactose Pharmatose 450 (Lactose 450, DFE Pharma, USA). The disintegrant Kollidon-CL (Crosprovidone, BASF, USA) and lubricant Magnesium Stearate (MgSt, Mallinckrodt Inc., USA) were added to every blend in congruence with previous studies (Han et al., 2013a; Huang et al., 2015b) , and to ensure adequate tablet disintegration during dissolution and lubrication during compaction respectively. Table 1 summarizes all the materials involved in this study, their manufacturers, particle sizes and functions. All particle size measurements reported in Table 1 were performed using a RODOS/ HELOS dry dispersion laser diffraction system (Sympatec, USA) at a dispersion pressure of 0.2 bar.
Dry coating of APIs
The two as received APIs (mAPAP and cAPAP) were dry coated using a Resonant Acoustic Mixer (LabRAM, Resodyn Corporation, USA). The API (50 g) along with 1 wt% (0.5 g) of nano-silica were put into a cylindrical plastic jar with height of 9.5 cm and inner diameter of 8 cm. The jar was clamped into the holder inside the LabRAM and shaken at high intensity (75 G's acceleration) for 5 min at a frequency of 60 Hz. A separate procedure was followed to produce dry coated, micronized Ibuprofen powder. As received Ibuprofen 90 was milled in a Fluid Energy Mill (FEM, Sturtevant, USA), which was operated at a feeding Table 1 The materials used in this study, along with their manufacturers, particle size data and functions. pressure of 20 psi, a grinding pressure of 15 psi and a feed rate of 5.9 g/ min. To control the feed rate of powder, a volumetric feeder (Schenck Accurate Model 102M, Schenck, USA) was calibrated with Ibuprofen 90 before use. At the end of the milling process, fine Ibuprofen powders were collected from the collecting filter of the FEM. The particle size data for this micronized Ibuprofen, along with that of the as received Ibuprofen 90, are presented in Table 1 . Then, to dry coat the milled Ibuprofen, 200 g worth, along with 2 g of nano-silica, were put in a 6-quart V-blender shell (Patterson Kelly, USA) and blended while a high shear intensifier bar (Patterson Kelly, USA) was rotating at a speed of 3600 RPM. The V-blender shell and intensifier bar were both rotating for the first 10 min, after which only the V-blender shell continued to rotate for an extra 20 min. The V-blender shell rotation speed was kept at 25 RPM throughout the 30 min of processing. Originally, LabRAM was used to dry coat FEM milled Ibuprofen powder, but significant property enhancement was not achieved. Higher intensity was needed to dry coat the milled Ibuprofen, and hence, the V-blender with intensifier bar was used.
Scanning electron microscopy
A Field Emission Scanning Electron Microscope (SEM, LEO 1530170, Carl Zeiss SMT Inc., Germany) was used to observe visual changes on the API particle surface after dry coating. Samples were sputter-coated with Carbon to enhance conductivity before taking SEM images (Q150T 16017, Quorum Technologies Ltd, Laughton, East Sussex, England).
Blend production
After dry coating, pharmaceutical blends were prepared, all of which were 60% drug loaded. A 0.5-pint V-blender (Patterson Kelly, USA) was filled with the API, filler/binder and disintegrant and run at 25 RPM for 12.5 min. Depending on the formulation, nano-silica was also added during this step, if needed. Then, the lubricant, MgSt was added and the mixture was blended for another 75 s at the same rotation speed. Table 2 displays the 10 blend formulations that were produced for each API. The nomenclature of each blend contains a letter and a number. The letters "L" and "F" denote whether the blend contains large or fine excipients respectively. Number "1" denotes that the blend contains no nano-silica, "2" denotes blends that contain hydrophobic R972P nano-silica coated API, "3" denotes hydrophobic R972P nano-silica added blends, "4" denotes hydrophilic M5P nano-silica coated API in the blend, and "5" for hydrophilic M5P nano-silica added blends. For silica added blends, the dry coating step described in Section 2.2 was not carried out, rather the nano-silica was introduced during the blend production step.
Blend characterization
The Freeman Technology FT4 (Freeman Technology Ltd, UK) was used to measure the bulk density (BD) and flow function coefficient (FFC) of the blends, which relate to bulk powder packing and flow respectively. For BD measurements, the program "1C split 1T" was used with the small (25 mm × 25 mL) vessel. For FFC measurements, the program "Shear_3kPa" was used with the large (50 mm × 85 mL) vessel. The shear test uses 3 kPa consolidation normal stress and performs shear tests at 2, 1.75, 1.5, 1.25 and 1 kPa normal stresses, at which incipient failure shear stresses were recorded. Then, the FT4 Data Analysis v4 software incorporated the shear test results to calculate the FFC, which is a ratio of major principle stress (MPS) to unconfined yield strength (UYS) (Schulze, 2007) . The physical interpretation of numerical FFC values are summarized in Table 3 ; and it is important to note that there are no physical differences between any numerical FFC values above 10. For both tests, a conditioning step was first carried out on the powder in order to normalize the powder condition and tests were done in triplicate for each blend. More detailed descriptions of BD test, Shear test, and data analysis can be found in literature (Freeman, 2007) .
Thermogravimetric analysis (TGA) was performed using the TGA/ DSC1/SF STAR e system (Mettler Toledo, Inc., Columbus, OH, USA) to detect moisture adsorption of blends. Three blends with cAPAP as the API were analyzed. Samples were stored in tightly sealed plastic bags at room temperature (20°C) and 26% relative humidity (RH) after production. 20 mg of each blend was placed in a ceramic crucible and heated with nitrogen flow from 25°C to 150°C at a constant rate of 10°C per minute. Each measurement was taken in duplicates, and very little variation was observed for each sample. Average values are reported.
Tablet production via direct compression
Tablets were produced from the pharmaceutical blends via the direct compression method. The Carver Platen Press (Carver Inc., USA) was used to make 10 mm diameter flat faced round tablets. First, 300 mg of powder was measured and placed in the die. Then, a certain compaction pressure was applied, which varied with the API used to make the pharmaceutical blend. At first, the L1 formulation of each API was compacted at various pressures and the tablet tensile strength was Table 2 The percentage composition of formulations used in this study. "L" signifies that the larger particle size excipients were used and "F" signifies the use of finer particle size excipients. "1" signifies no silica was used in the formulation, "2" and "4" are formulations in which the API was dry coated with hydrophobic and hydrophilic silica respectively, and "3" and "5" are formulations in which the hydrophobic and hydrophilic silica, respectively, were simply added to during the mixing step. Table 3 The physical meaning of FFC values (Schulze, 2007) .
Easy Flowing FFC ≥ 10 Free Flowing K. Kunnath et al. International Journal of Pharmaceutics 543 (2018) 288-299 evaluated. The compaction pressure which created an L1 tablet with tensile strength just below 2 MPa, which was recommended in previous literature (Sun, 2010) , was chosen as the compaction pressure for that specific API. The compaction pressures of the blends are as follows: 4 Metric Tons for cAPAP blends, 1.5 Metric Tons for mAPAP blends, and 1 Metric Ton for mIBU blends. These pressures correlate to approximately 500 MPa, 187 MPa, and 125 MPa respectively.
Tablet tensile strength analysis
Tablets were analyzed for their tensile strength with the Texture Analyzer (Texture Technologies Corp. USA). The force at which each tablet broke while under compressional loading on its side was measured and recorded. The tablet breakage force (F), along with tablet diameter (D t ) and thickness (t) were used to calculate the tensile strength (σ) of the tablet using Eq. (1) (Fell and Newton, 1970 ).
Tablet dissolution analysis
Dissolution of tablets was performed using the USP II paddle method via the Distek 2100C, along with its temperature control system, TCS 0200 (Distek Inc., USA). Phosphate buffer solution (PBS) was used as the dissolution medium and each tablet was dissolved in 900 mL of solution. For cAPAP and mAPAP tablets, PBS pH 5.8 was used while PBS pH 7.2 with 0.04 g/mL sodium dodecyl sulfate (SDS) added was used for mIBU tablets, which is in accordance with USP guidelines. The temperature of the dissolution media was kept at 37°C ± 0.2°C, and the paddle rotating speed was set to 50 RPM. The tablet was put in the dissolution medium and 6 mL samples were taken at each predetermined time point (2, 5, 10, 15, 30, 45, 60 and 120 min) . All samples were filtered through a 0.45 μm filter to separate out drug that was not dissolved in the sample at the time of collection. After filtration, each sample was diluted 10-fold, then assessed using the Thermo Evolution UV spectrophotometer (Thermo Scientific Inc., USA). For cAPAP and mAPAP tablet dissolutions, the UV wavelength was set to 243 nm, while 222 nm was used for mIBU tablets. Experimental values of tablet dissolution absorbance in UV was correlated to percent of API dissolved via calibration curve, which was compiled before commencing dissolution studies. For each blend, dissolution was done for 3 tablets with average percent API dissolved for each time point reported. (Fig. 1a ) and dry coated with either hydrophobic (Fig. 1b) or hydrophilic nano-silica (Fig. 1c) . A smooth API particle surface can be observed for uncoated cAPAP (Fig. 1a) . After dry coating, SEM images show the attachment of nano-silica onto the API particle surface. The surface coverage is greater and more uniform with hydrophobic R972P nano-silica (Fig. 1b) compared to hydrophilic M5P nano-silica (Fig. 1c) , which is in agreement with previous literature (Huang et al., 2015a) . In light of this, it is expected that hydrophobic R972P nano-silica dry coated APIs have lower interparticle cohesion forces (Huang et al., 2015a; Jonat et al., 2004) , and thus, better blend properties.
Results and discussion
Scanning electron microscopy
Bulk density of pharmaceutical blends
Bulk density of a pharmaceutical blend is an important factor to consider when deciding its potential use in direct compression (Sun, 2010; Thoorens et al., 2014) . Adequate bulk density is indicative of good packing in the powder bed, which is necessary to produce tablets of ample tensile strength (Jivraj et al., 2000) . In Fig. 2 , it can be observed that dry coating of APIs improves the bulk density of pharmaceutical blends. These results are in agreement with previous research (Capece et al., 2014; Han et al., 2013a; Huang et al., 2015b) , and the trend holds true regardless of API, guest particles or excipients used to make pharmaceutical blends. All but one of the dry coated blends meet the minimum standard of 0.3881 g/mL required for use in direct compression (Shi et al., 2011) . The exception being the blend of mAPAP dry coated with hydrophilic nano-silica and fine excipients, at 0.38 g/mL, which just about meets the minimum standard.
It is important to note that nano-silica dry coated API blends consistently out perform their silica added blend counterparts. Meaning, for all APIs, the L2, L4, F2 and F4 blends have higher bulk densities than the L3, L5, F3 and F5 blends respectively. This trend is expected based on previous research (Capece et al., 2014 , Han et al., 2013 Huang et al., 2015a,b) , and highlights the advantage of dry coating APIs as opposed to simply adding a glidant into the mixing step. These trends are attributed to decreased API cohesion (Capece et al., 2014; Chen et al., 2008; Yang et al., 2005) , and associated deagglomeration of the API . Moreover, the improvement is more significant in the case of high drug loaded blends (Han et al., 2013a) .
When examining the effect of excipient size on the bulk density of blends, the trend shows that large excipient blends generally have higher bulk densities and in the case of dry coated API blends, large excipient blends always have higher bulk densities. This may be due in part to multimodal particle size distributions (German, 1989) , since the API and excipients generally have almost an order of magnitude difference in terms of median particle size. Another reason may be due to the cohesive nature of the fine excipients used, which may lead to agglomeration and sub-optimal packing (Castellanos, 2005; Jallo et al., 2012) of both the excipient and blend.
In terms of the choice of guest particles, hydrophobic R972P nanosilica dry coated API blends consistently have higher bulk densities than hydrophilic M5P nano-silica dry coated API blends. This may be since hydrophobic R972P nano-silica requires less intense mixing to garner the same surface area coverage (See Fig. 1 ) onto the API, and due to the lower surface energy of hydrophobic M5P nano-silica compared to hydrophilic (Huang et al., 2015a; Jonat et al., 2004) .
Flowability of pharmaceutical blends
Flow of powders into a tablet die must be adequate, predictable and consistent to ensure uniform tablet weight and drug content (Thoorens et al., 2014) . Fig. 3 displays the flow function coefficients (FFC) of all the pharmaceutical blends used this study. It is evident that dry coating of APIs improves the FFC of pharmaceutical blends, in line with previous research (Capece et al., 2017; Han et al., 2013a; Huang et al., 2015b) . The flow improvements can be attributed to the reduction in inter-particle cohesion after dry coating (Capece et al., 2015 (Capece et al., , 2016 Chen et al., 2008; Yang et al., 2005) .
Unlike all the bulk density results, correlating flow improvement to excipient particle size is not straight forward. In all cases when the API is dry coated, the flow improvements of blends are more significant that when they are not dry coated, regardless of inclusion of silica in the blends. Focusing only on blends with dry coated API, for cAPAP blends, large excipient blends have higher FFC values than their fine excipient counterparts, whereas the opposite is true for mAPAP and mIBU blends; fine excipient blends have higher FFC values than their large excipient counterparts. It is noted that apart from cAPAP being larger than mAPAP or mIBU, it also has a very wide size distribution, including a d 90 particle size of over 90 µm. Interestingly, previous work concluded that powders with smaller mean particle size, yet narrower particle size distribution could have higher FFC values than powders with higher mean particle size and a wider particle size distribution (Liu et al., 2008) . Nonetheless, Liu et al. did not include cohesive powders with median particle sizes below 25 µm, as is the case in this study, and clearly did not consider dry coating, which may not have been necessary (Liu et al., 2008) .
Finally, as was the case for bulk density, hydrophobic nano-silica dry coated API blends have higher FFC values than hydrophilic nanosilica dry coated API blends, attributed to the superior API surface area coverage coating for hydrophobic nano-silica, along with its lower dispersive surface energy (Huang et al., 2015b; Jonat et al., 2004) .
Processability or regime map: bulk density vs FFC
In order to discern the improvements in powder packing and flowability simultaneously, processability maps that were intended to represent regimes of granulation or direct compaction have been presented in previous studies with bulk density as the x-axis and FFC as the y-axis Han et al., 2013a; Huang et al., 2015b; Mullarney et al., 2011) . In these figures, quadrants are created by lines which represent what may be considered as standard acceptance values. Clearly, these demarcations need further work. However, initial guidelines for the x-axis could be bulk density of 0.3881 g/mL and for the y-axis could be FFC of 8.36; both are based on the powder characteristics of Avicel 102, an excipient commonly used in direct compression processing (Shi et al., 2011) . Ideally, blends in consideration for direct compression tableting should fall in the top right quadrant; meaning they have both bulk density and FFC values above the respective standards. Micronized, cohesive APIs typically fall into the bottom left quadrant, and those blends are expected to need granulation processing before tableting (Huang et al., 2015b) . A great advantage of such a map is that the relative movement upwards and towards the right in this regime map is an indication of the efficacy of the processing technique and/or formulation to improve blend properties. A representative cartoon for a typical processability map is provided as Fig. S1 in the Supplementary material which shows that the regimes need not be rectangular, and while not explicitly shown, their boundaries can overlap. The axes for the processability maps are kept the same so visual comparisons of packing and flow improvement can be easily interpreted. Fig. 4 displays the processability maps which include all the blends used in this study. Blend property improvements can be visualized as there is movement up and towards the right in the diagrams when starting with the no silica blends (circles) and ending with the dry coated blends (squares and stars). It can be observed that in all processability maps of Fig. 4 that hydrophobic dry coated API blends (squares) consistently have either the best, or almost the best blend properties. Another important point evident in all the processability maps is that there are significant improvements from silica added blends (diamonds and hexagrams) to the respective nano-silica dry coated blends (squares and stars).
When evaluating the cAPAP processability map (Fig. 4a) , it is evident that large excipient blends (open markers) have better simultaneous bulk density and flow improvement after dry coating; the fine excipient blends (dark markers) are lacking flow improvement for hydrophilic M5P nano-silica formulations (stars and hexagrams). However, when examining the micronized API processability maps (Fig. 4b,  c) , one trend to note is that fine excipients (dark markers) have better Fig. 1 . Scanning electron microscopy (SEM) images of (a) as received, uncoated cAPAP, (b) hydrophobic nano-silica (R972P) dry coated cAPAP, and (c) hydrophilic nano-silica (M5P) dry coated cAPAP at 10 k× magnification.
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Thermogravimetric analysis of blends
The results of TGA analysis of three blends with cAPAP as the API are reported in Table 4 . It is noted that all powders, blends and tablets were stored at the same room temperature (20°C) and RH of 26%. After dry coating the API, the moisture content of the blends increases only slightly, for both hydrophobic and hydrophilic nano-silica dry coated cAPAP blends. However, there is negligible difference between hydrophobic and hydrophilic dry coated API blends. Specifically, the moisture content in the blend went from 1.70 wt% (uncoated API blend) to 1.82 wt% (hydrophobic R972P nano-silica dry coated API blend) and 1.80 wt% (hydrophilic M5P nano-silica dry coated blend). It was previously reported that increasing moisture content is detrimental to flow properties (Sun, 2016) . However, it has also been reported that after dry coating cohesive powders, the reduction in interparticle force can have a stronger impact on bulk properties compared to increased moisture content (Chen et al., 2018) . The trends attained in this study, and previous studies (Han et al., 2013a; Huang et al., 2015b) which did not investigate moisture content of blends, all agree that the reduction of interparticle cohesion outweighs the effects of increased moisture content.
Tensile strength of tablets
In order to withstand the rigors of processing and handling after compaction, tablets must have adequate tensile strength, otherwise breakage or chipping of the tablet is sure to occur. Sun et al. suggest a tensile strength of 2 MPa as a standard, below which tablets are considered to not be able to withstand such rigors (Sun, 2010) . It is expected that dry coating of powders would lead to decreased tablet tensile strength (Chen et al., 2018) . However, previous work demonstrated that using dry coated API in a pharmaceutical blend can lead to tablets which meet the 2 MPa standard (Huang et al., 2015b) . In this work, the aim is not to achieve this tensile strength standard, but rather to investigate which formulation will achieve the best improvements in tablet tensile strength. From all three API blends shown in Fig. 5 , it is evident that dry coating the API improves the tensile strength of tablets more than by simply adding nano-silica to the formulation, and is in agreement with previous studies (Han et al., 2013a; Huang et al., 2015b) . It is noted that the compaction pressures employed in this work are lower than those in previous work (Han et al., 2013a; Huang et al., 2015b) . There are several possible mechanisms which bring about this trend. One is that the presence of nano-silica, whether dry coated onto API or simply added, facilitates the rearrangement of particles during compression (Huang et al., 2015b) . Another possible explanation is that dry coating of APIs lead to deagglomeration of the powder, which in turn creates higher total surface area in the powder bed. The bonding area bonding strength (BABS) model proposed by Sun et al. suggests the higher total surface area will lead to higher tablet tensile strengths (Sun, 2011 ). This effect is compounded by the fact that all blends are K. Kunnath et al. International Journal of Pharmaceutics 543 (2018) 288-299 high drug loaded, meaning the dry coated API makes up the majority of the blend, and thus have significantly more impact on powder properties. It has been previously stated that dry coating the API can only significantly improve tablet tensile strength of pharmaceutical blends at high drug loadings (Han et al., 2013a) , and the results of this study verify this conclusion in a more general sense with various APIs. When comparing the effect of excipient particle size on tablet tensile strength, the general trend shows that the inclusion of fine excipients are beneficial. This is in agreement with both previous experimental work (Fell and Newton, 1970; Huang et al., 2015b) , as well as the BABS model (Sun, 2011) . Finer particle size excipients equate to higher total surface area, which create more available bonding area during the compression of the tablet, and translate to higher tablet tensile strengths. Hydrophilic M5P nano-silica blends, either dry coated or silica added, display much higher tablet tensile strengths compared to their hydrophobic R972P nano-silica counterparts. In some cases, hydrophilic M5P nano-silica added blends outperform hydrophobic R972P dry coated API blends, providing the excipient particle size is the same. Given that the particle size of both types of nano-silica are similar, and hydrophobic R972P nano-silica dry coating achieves superior API surface area coverage, this is an indication that hydrophilic M5P nano-silica possess an intrinsic property with creates higher bonding strength during compaction.
It is commonly known that the addition of liquid into the blend, perhaps by adsorption onto the hydrophilic nano-silica, would lead to higher total cohesion force in hydrophilic nano-silica blends. However, previous work has shown that hydrophilic nano-silica, despite its hydrophilic nature, does not always have hygroscopic behavior compared to hydrophobic nano-silica (Kojima and Elliott, 2013; Xanthakis et al., 2015) . Additionally, TGA analysis done in this study, and discussed in Section 3.5, demonstrate negligible differences in moisture content of hydrophobic and hydrophilic nano-silica dry coated API blends. It has been previously reported that the surface energy of M5P nano-silica (44.68 mJ/m 2 ) is much higher compared to R972P nanosilica (34.00 mJ/m 2 ) (Huang et al., 2015a) , and such a difference could be the reason for increased bonding strength, thus higher tablet tensile strength (El Gindy and Samaha, 1982; Etzler et al., 2011; Fichtner et al., 2008) . This makes the higher tablet tensile strength of hydrophilic nano-silica blends an interesting topic for further research. The trends mentioned in this section so far are visible, but much less drastic for the mIBU blends. This may be due the fact that Ibuprofen is less cohesive and may be a slightly better compacting API compared to Acetaminophen. Even the mIBU blends without silica already meet the tablet tensile strength standard at just one metric ton compaction force.
When assessing the effect of formulations changes on a tablet, it is important to isolate the effect of porosity or solid fraction, as this can dictate tablet performance. Table 5 displays the average solid fractions of the tablets produced from each blend investigated in this study. In general, solid fractions for different API blends generally differ, where those of mAPAP have the lowest values. However, the differences in solid fractions of tablets within each API group are small. To further examine this effect, Fig. 6 shows the compactability results (tensile strength vs. porosity) of all the tablets. The plot shows significant scatter, and it would be difficult to discern any distinct pattern. Overall, there is much smaller difference in the solid fraction/porosity between different formulations, as compared with rather larger differences in tablet tensile strengths. Therefore, it can be concluded that the formulation and processing have a more dominant effect than the tablet solid fraction.
Processability map: FFC vs tensile strength
A new processability map, which has not been presented for pharmaceutical blends before, has blend FFC as the x-axis and tablet tensile strength as the y-axis. This setup displayed in Fig. 7 , offers users a way to simultaneously compare improvements in blend flowability and compaction. The FFC standard is the same as in the first set of processability maps (8.36) and the tablet tensile strength standard is 2 MPa, as discussed in Section 3.4 (Sun, 2010) . These processability maps can be analyzed in a similar fashion as the first set of processability maps; blends considered adequate for direct compression should fall in the top right quadrant of the processability map.
A major conclusion that can be drawn from these maps is the distinct feature of fine excipients in enabling simultaneous improvements in compaction and flow. In Section 3.3, it was concluded that in order to get the best improvements in flow, it is best to use excipients that have similar particle size as the API. When examining Fig. 7a , it can be seen that large excipients (dark markers) offer good flow improvements for cAPAP blends, but do not offer enough improvement in terms of compaction. The only exception is in the case of hydrophilic M5P nano-silica coated API, which has adequate tablet tensile strength. On the other hand, fine excipients offer adequate compaction, but do not offer enough improvements in flow unless hydrophobic R972P nano-silica is used in formulation. However, there is no indication that the use of hydrophobic R972P nano-silica would lead to additional improvement in tablet tensile strength for large excipient blends. Therefore, it can be concluded that the use of fine excipients offers better simultaneous improvement in both blend flowability and tablet tensile strength, and this trend is best visualized using the type of processability maps from Fig. 7 .
Another important trend to note from these processability maps is the superiority of hydrophilic M5P nano-silica when used as a dry coating guest. For both cAPAP and mAPAP blends in Fig. 7a, b , it can be observed that hydrophilic M5P nano-silica dry coated API blends (stars) have significant, positive movement in both x and y directions, indicating simultaneous powder flow and compaction improvement. Meanwhile, hydrophobic R972P nano-silica dry coated API blends (squares) generally show good improvement in the x-axis, but not the y- axis. It is important to note that the mIBU blends without silica (circles) in Fig. 7c already meet the tablet tensile strength standard, and only flow improvements are necessary. In this case, either type of nano-silica combined with fine excipients may be used in formulation, since this combination offers the most flow improvement.
Dissolution of tablets
Faster dissolution of API is beneficial for most tablet applications because it will lead to increased bioavailability, thus a quicker and/or stronger therapeutic response. It is expected that fine powders and hydrophilic materials dissolve faster due to increased available surface area (Liversidge and Cundy, 1995) and increased wettability respectively (Han et al., 2011; Hillery and Florence, 1996) , and these hypotheses are examined in this sub-section. Although dissolution testing was done for all blends produced in this study, only the dry coated API and no silica tablet dissolutions will be presented, to avoid overcrowding of figures. Fig. 8 displays the dissolution profiles of the tablets in order to better understand how dry coating, excipient particle size and guest hydrophilicity influence the dissolution rates. It is to be noted that dissolution profiles are only shown for 20 min for each blend, and although not apparent in these figures, full API dissolution was achieved with prolonged dissolution time.
In general, dry coated API blends had either faster or about the same dissolution as the blends without silica. So in the very least, it can be said that dry coating generally does not negatively affect dissolution, which agrees with previous literature (Han et al., 2013a) . The only instance where dry coating negatively affected the dissolution rate was for mAPAP tablets with fine excipients (dashed lines in Fig. 8b ). API dissolution is initiated by tablet disintegration, during which the dosage form breaks down into large agglomerate chunks, and delays in this phase can lead to slower dissolution rates (Najib and Jalal, 1988) . The dry coated API and fine excipient mAPAP tablets (dashed lines with markers in Fig. 8b ) have much higher tablet tensile strength compared to the fine excipient, no silica tablet (dashed line without markers in Fig. 8b ). This results in slower dissolution profiles most likely due to delayed disintegration. Although all other dry coated API tablets have higher tablet tensile strengths compared to the no silica cases, the difference may not be enough to impact tablet dissolution. It is also important to consider that dry coating causes deagglomeration of the API , which creates higher available surface area and increased dissolution rates. For the tablets in this study, the deagglomeration of the API and increased tablet tensile strength are both outcomes of dry coating the API, but have confounding effects on API dissolution rate from the tablet. From an industrial perspective, it would be advantageous to dry coat API for bulk powder property enhancement, but lower compressive forces should be used during compaction, in order to minimize tablet disintegration time.
Generally, fine excipient tablets (dashed lines in Fig. 8 ) have slower dissolution rates compared to their corresponding large excipient tablets (solid lines in Fig. 8 ). Again, this can be attributed to longer disintegration time due to higher tablet tensile strengths when finer excipients are used in formulation (Najib and Jalal, 1988; Riippi et al., 1998; Sinka et al., 2009) . It is expected that hydrophilic M5P nanosilica dry coated API tablets should have faster dissolution compared to their hydrophobic R972P nano-silica dry coated API tablets, via increased wettability (Hillery and Florence, 1996; Kumar et al., 2014; Li et al., 2017) . This is generally true for the tablets used in this study, assuming API and excipient particle sizes are held constant. However, hydrophobic R972P nano-silica dry coated API tablets were not expected to have faster dissolution rates compared to the tablets which have no silica. It was hypothesized that the hydrophobic R972P nanosilica would negatively affect the wettability of the API surface, thus slowing down dissolution rates (Carrstensen et al., 1992; Lindman et al., 2010; Repka et al., 2018; Zhang et al., 2017) . Except for the mAPAP fine excipient tablets, where tablet tensile strengths and disintegration may be delaying API dissolution, hydrophobic R972P nanosilica dry coated API tablets have either similar or faster dissolution compared to the no silica case. It can be said that even if the dry coating guest is hydrophobic, dissolution rates may not be slower, and previous literature has presented similar results (Qu et al., 2015) . Such results can be attributed to the increase in surface area via deagglomeration of the micronized API after dry coating with hydrophobic R972P nanosilica (de Villiers, 1996; Huang et al., 2017). Higher available surface area of API leads to faster dissolution rates (Noyes and Whitney, 1897) , a phenomena which competes with silica surface hydrophobicity for influence over API dissolution rate. In this study, deagglomeration and increased surface area tend to dominate over surface hydrophobicity of API imparted by the dry coating guest.
Conclusions
The effects of dry coating, excipient particle size and guest particle hydrophilicity on high drug loaded blend and tablet properties were all investigated for three different fine, cohesive APIs. As proven in previous studies, dry coating cohesive APIs with nano-silica helps improve various properties, stemming from the ability of nano-silica to lower the inter-particle force of the cohesive APIs. Blend packing (bulk density) and flow (FFC) were improved after dry coating the APIs, with either hydrophobic or hydrophilic nano-silica. Generally, hydrophobic nanosilica (R972P) dry coated API blends had better blend properties compared to hydrophilic nano-silica (M5P) dry coated API blends. These results further validate the advantages of dry coating in flow and bulk density enhancements for APIs and their blends. A major novelty of the current results stem from the fact that although better blend flowability is expected with the inclusion of larger excipients, even better blend flow can be attained if dry coated, fine micronized APIs (mAPAP and mIBU) are paired with fine excipients. Regarding the impact of silica coating and excipient size on tablet tensile strength, it increased regardless of the hydrophobicity of the silica (1) for dry coated API blends compared to uncoated API blends, and (2) when fine excipients were used instead of coarse excipients in dry coated API blends. Not surprisingly, the use of hydrophilic nano-silica (M5P) dry coated APIs showed higher tablet tensile strengths compared to hydrophobic nano-silica (R972P) dry coated APIs. The most surprising results were that dry coating APIs was shown not to have negative effect on drug dissolution from the tablets even if the APIs were dry coated with hydrophobic silica, with an exception of mAPAP, where the strong dependence on tablet hardness lead to slower dissolution rates, perhaps via slower tablet disintegration. Due to this same dependence on tablet hardness, fine excipient blends generally showed slower dissolution rates compared to large excipient blends. While not investigated, this deficiency may be eliminated by compressing those tablets at lower compaction forces, while still achieving adequate tablet hardness and hence, avoiding negative impact on dissolution. Finally, tablet dissolution results show that hydrophilic nano-silica (M5P) dry coated API tablets have much faster dissolution, as expected, but hydrophobic nano-silica (R972P) dry coated API tablets still have faster dissolution rates compared to uncoated API tablets, again with the exception of mAPAP blends. Overall these results establish a universal benefit of dry coating cohesive APIs in significantly improving key blend properties that increase the drug loadings, even with fine excipients, for direct compression tableting, without negatively impacting tablet strength or drug dissolution.
